Skip to main content
    O

    Oculis Holding AG Ordinary shares (OCS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.63
    -0.01 (-0.13%)

    Market Cap: $425.67M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Oculis Holding AG Ordinary shares (OCS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Oculis Holding AG Ordinary shares are Ocugen (OCGN), Ovid Therapeutics (OVID) and Opus Genetics (IRD). By market cap, Oculis Holding AG Ordinary shares ranks 9th of the 13 companies on this page; Ocular Therapeutix (OCUL) is the largest at $1.37B.

    Peer Comparison

    OCS's revenue growth of -97.1% is below the peer median of -5.8%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Oculis Holding AG Ordinary shares (OCS)$425.67MN/AN/A0.0%N/A-97.1%0.00%
    Ocugen Inc (OCGN)$280.88MN/A54.9x0.0%271.0%11.4%0.00%
    Ovid Therapeutics Inc (OVID)$479.38MN/A335.8x0.0%N/A-88.3%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Ocular Therapeutix Inc (OCUL)$1.37BN/A26.9x0.0%-52.1%-11.5%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Orchestra BioMed Holdings Inc. (OBIO)$570.61MN/A14.7x-182.5%-97.0%-89.4%0.00%
    Tevogen Bio Holdings Inc. (TVGN)$406.59MN/AN/A0.0%2022.8%0.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Tectonic Therapeutic, Inc. (TECX)$413.27MN/AN/A0.0%N/A0.0%0.00%
    Peer median$464.04MN/A29.0x0.0%-32.8%-5.8%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Oculis Holding AG Ordinary shares, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ocugen Inc (OCGN)
    Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness.
    OCGN competitors
    Ovid Therapeutics Inc (OVID)
    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States.
    OVID competitors
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    Ocular Therapeutix Inc (OCUL)
    Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development...
    OCUL competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Orchestra BioMed Holdings Inc. (OBIO)
    Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases.
    OBIO competitors
    Tevogen Bio Holdings Inc. (TVGN)
    Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology...
    TVGN competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
    Tectonic Therapeutic, Inc. (TECX)
    Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel...
    TECX competitors

    Frequently Asked Questions About OCS

    Who are Oculis Holding AG Ordinary shares' main competitors?

    The companies most similar to Oculis Holding AG Ordinary shares include Ocugen (OCGN), Ovid Therapeutics (OVID), Opus Genetics (IRD), Ocular Therapeutix (OCUL) and Olema Pharmaceuticals (OLMA), listed from the closest match.

    Who is Oculis Holding AG Ordinary shares' biggest competitor?

    Ocular Therapeutix (OCUL) is the largest of the similar companies at $1.37B; Ocugen (OCGN) is the closest match by business profile, size, sector and industry.

    How does OCS stock compare with its competitors?

    OCS' net margin is 0.0% against a peer median of 0.0%.

    Which of Oculis Holding AG Ordinary shares' competitors pays a higher dividend?

    Oculis Holding AG Ordinary shares pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Oculis Holding AG Ordinary shares bigger than its competitors?

    No. Oculis Holding AG Ordinary shares is 9th by market cap among the 13 companies on this page; the largest is Ocular Therapeutix (OCUL) at $1.37B.